IMPACT Therapeutics Defines New Nomination Committee Framework to Strengthen Board Governance

Bulletin Express06:22

IMPACT Therapeutics, Inc. released the “Terms of Reference of the Nomination Committee of the Board of Directors,” outlining a revamped governance framework aimed at optimizing board composition and succession planning.

Key features:

1. Committee Composition • Minimum of three directors; a majority must be independent non-executive directors. • At least one committee member must be of a different gender to foster diversity. • The chair is either the Board chairman or an independent non-executive director and is appointed by the Board.

2. Core Responsibilities • Develop selection criteria, search processes and reserve plans for directors and senior management, considering culture, education and professional experience. • Annually review the Board’s structure, size, skills matrix and diversity policy, and recommend adjustments aligned with corporate strategy. • Assess the independence of proposed independent non-executive directors and disclose the evaluation process in shareholder circulars. • Monitor directors’ time commitment, integrity and professional qualifications, with specific compliance checks against Hong Kong Listing Rules. • Support performance evaluations of the Board and its committees, providing succession recommendations for key roles such as chairman and general manager.

3. Operating Procedures • Hold at least one regular meeting each year; extraordinary meetings can be convened by the committee chair, more than half of its members or the Board chairman. • Meetings require a two-thirds quorum, including at least one independent non-executive director. • Decisions are passed by majority vote; the chair holds a casting vote in case of a tie. • Written minutes must record discussions in detail and be accessible to any director on request.

4. Recusal and Conflict-of-Interest Rules • Members with direct or indirect interests in agenda items must declare such interests and may be required to abstain from voting. • If recusals reduce attendance below quorum, matters are escalated to the full Board for resolution.

5. Resource Allocation and Transparency • The company must provide sufficient resources for the committee’s work, including external advisers when necessary. • The full Terms of Reference will be posted on both the Hong Kong Stock Exchange and company websites upon listing of the company’s H shares.

The new Terms of Reference will come into effect once IMPACT Therapeutics’ H shares commence trading on the Hong Kong Stock Exchange, reinforcing the company’s commitment to enhanced corporate governance and board diversity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment